Sotera Health (NASDAQ:SHC) Stock Holdings Lifted by Inherent Group LP

Inherent Group LP grew its holdings in Sotera Health (NASDAQ:SHC) by 79.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 281,251 shares of the company’s stock after purchasing an additional 124,421 shares during the quarter. Sotera Health comprises approximately 2.9% of Inherent Group LP’s portfolio, making the stock its 8th largest holding. Inherent Group LP owned approximately 0.10% of Sotera Health worth $3,338,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of SHC. Janus Henderson Group PLC lifted its stake in Sotera Health by 43.6% in the 1st quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock worth $178,865,000 after purchasing an additional 4,525,056 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Sotera Health by 27.0% during the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock valued at $145,863,000 after buying an additional 2,579,248 shares during the period. Khrom Capital Management LLC purchased a new stake in shares of Sotera Health during the 1st quarter valued at approximately $14,626,000. Norges Bank purchased a new stake in shares of Sotera Health during the 4th quarter valued at approximately $16,432,000. Finally, Tyro Capital Management LLC purchased a new stake in shares of Sotera Health during the 4th quarter valued at approximately $15,761,000. 91.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently commented on SHC. Barclays lifted their price target on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 price target on shares of Sotera Health in a research report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and an average target price of $15.70.

Sotera Health Stock Down 0.1 %

Shares of NASDAQ SHC opened at $16.64 on Tuesday. The firm has a market cap of $4.71 billion, a price-to-earnings ratio of 87.58 and a beta of 2.07. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The business’s 50 day moving average is $14.96 and its two-hundred day moving average is $12.86.

Sotera Health (NASDAQ:SHC) last announced its earnings results on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.15 by $0.04. The company had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 earnings per share. Research analysts predict that Sotera Health will post 0.64 EPS for the current year.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the business’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now owns 49,215,301 shares in the company, valued at $739,705,974.03. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 55.12% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.